시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 희소 혈액학 시장 보고서(2025년)
Rare Hematology Global Market Report 2025
상품코드 : 1855972
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,707,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,694,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,682,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

희소 혈액학 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 144억 6,000만 달러로 평가되었고, 2025년에는 154억 7,000만 달러에 달하고, CAGR 7.0%로 성장할 전망입니다. 역사적인 기간에 있어서의 성장의 원동력이 된 것은 전문 치료 센터의 이용 가능성 증가, 혈액학에 있어서의 학술 연구 자금 증가, 희소 혈액 질환에 대한 의사의 의식 증가, 바이오뱅크와 등록의 이용 확대, 서베이런스 시스템의 강화에 의한 발병 보고의 개선 등입니다.

희소 혈액학 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.6%로 199억 8,000만 달러로 성장할 전망입니다. 예측기간 동안의 성장은 표적생물제제의 파이프라인 증가, 정밀진단 채택 증가, 희소질환 연구를 위한 국경을 넘어 공동연구 확대, 환자지원을 위한 디지털 플랫폼 연구개발, 예방적 유전 상담의 중시 증가에 의해 촉진됩니다. 예측 기간의 주요 동향으로는 면역요법 접근법의 진보, 줄기세포 이식법의 개선, 혈액학에서의 디지털 헬스 플랫폼의 통합, 기술 주도의 창약 모델, 바이오마커에 근거한 진단법의 개발 등을 들 수 있습니다.

희소 혈액 질환의 유병률 증가는 향후 수년간 희소 혈액학 시장의 성장을 가속할 것으로 예측됩니다. 희귀 혈액 질환은 혈액 세포와 응고 인자의 생산, 기능, 수명에 영향을 미치고 빈혈, 출혈 및 용혈을 일으키는 드문 질병입니다. 이러한 질병의 유병률이 상승하고 있는 것은 주로 유전자 변이나 유전성 질환에 의한 것으로, 이상한 유전자가 부모로부터 아이에게 계승됩니다. 희소 혈액학 시장은 복잡하고 특이한 혈액 질환 관리에 이상적인 전문 진단 및 표적 치료를 제공함으로써 이러한 질병에 대한 대응에 중요한 역할을 수행합니다. 이러한 서비스는 정확한 치료와 지속적인 환자 관리를 가능하게 함으로써 합병증을 줄이고 궁극적으로 건강 결과와 삶의 질을 향상시킵니다. 예를 들어, 2024년 4월 호주에 본사를 둔 비영리 단체인 퍼스 블러드 연구소는 혈액응고를 방해하는 유전성 혈액 질환인 혈우병으로 진단받은 사람의 수가 2021년 23만 3,577명에서 2022년 25만 7,146명으로 증가했다고 보고했습니다. 그 결과, 희소 혈액 질환의 만연이 희소 혈액학 시장의 확대에 박차를 가하고 있습니다.

희소 혈액학 시장의 기업은 암멧 의료 요구에 대응하고 환자 지원을 강화하고 다양한 질병의 해결책을 추진하기 위해 혁신적인 치료법의 개발과 멀티스테이크 홀더 광고 협의회 등 전략적 이니셔티브의 확립에 점점 힘을 쏟고 있습니다. 멀티스테이크홀더 어드보카시 협의회는 환자, 간병인, 전문가를 모아 특정 건강상태의 케어, 인지도, 해결책의 개선에 협력합니다. 예를 들어, 2023년 2월 미국 바이오 의약품 회사인 아기오스 퍼머슈티칼스는 적혈구 혁명 어드보카시 자문위원회를 시작했습니다. 이 이니셔티브는 피루브산 키나아제 결핍증, 살라세미아, 겸상 적혈구증과 같은 희귀 용혈성 빈혈에 중점을 둡니다. 이 협의회는 지역사회와의 연계를 강화하고, 공표된 증거를 만들고, 실용적인 해결책을 창출하고, 공통의 과제에 대한 인식을 높이는 것을 목적으로 하고 있습니다. 여기에는 스폰서가 있는 팟캐스트, 비디오 컨텐츠, 전국 희소질환단체연합회(National Organization for Rare Disorders) 등의 조직과의 파트너십 등의 노력이 포함되어 건강의 공정성과 교육을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Rare hematology refers to the study, diagnosis, and treatment of uncommon blood disorders, including rare anemias, clotting disorders, bone marrow failure syndromes, and rare blood cancers. These conditions often affect small patient populations and have limited treatment options. Rare hematology advances understanding, improves diagnosis, and supports the development of targeted therapies to enhance patient outcomes and quality of life.

The primary disease types in rare hematology include hemophilia, sickle cell disease, thalassemia, myelodysplastic syndromes, and others. Hemophilia is a genetic bleeding disorder characterized by insufficient clotting factors, leading to excessive bleeding and difficulty controlling hemorrhages. Treatments include gene therapy, stem cell transplantation, blood transfusion, and pharmacotherapy, supported by diagnostic techniques such as laboratory tests, blood tests, bone marrow biopsies, imaging methods, MRI scans, ultrasounds, genetic testing, carrier screening, and whole genome sequencing. Applications span both pediatric and adult populations, serving end users including hospitals, specialty clinics, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The rare hematology market research report is one of a series of new reports from The Business Research Company that provides rare hematology market statistics, including rare hematology industry global market size, regional shares, competitors with a rare hematology market share, detailed rare hematology market segments, market trends and opportunities, and any further data you may need to thrive in the rare hematology industry. This rare hematology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare hematology market size has grown strongly in recent years. It will grow from $14.46 billion in 2024 to $15.47 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period was driven by increasing availability of specialized treatment centers, rising academic research funding in hematology, growing physician awareness of rare blood conditions, expanding use of biobanking and registries, and improved incidence reporting through enhanced surveillance systems.

The rare hematology market size is expected to see strong growth in the next few years. It will grow to $19.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period is fueled by a growing pipeline of targeted biologics, rising adoption of precision diagnostics, expanding cross-border collaborations for rare disease research, development of digital platforms for patient support, and increasing emphasis on preventive genetic counseling. The primary trends in the forecast period include advancements in immunotherapy approaches, improvements in stem cell transplantation methods, integration of digital health platforms in hematology, technology-driven drug discovery models, and developments in biomarker-based diagnostics.

The increasing prevalence of rare blood disorders is expected to drive the growth of the rare hematology market in the coming years. Rare blood disorders are uncommon conditions that affect the production, function, or lifespan of blood cells or clotting factors, leading to anemia, bleeding, or hemolysis. The rising prevalence of these disorders is primarily due to genetic mutations and inherited conditions, where abnormal genes are passed down from parents to children. The rare hematology market plays a crucial role in addressing these conditions by providing specialized diagnostics and targeted therapies, ideal for managing complex and uncommon blood disorders. These services reduce complications by enabling precise treatment and continuous patient care, ultimately improving health outcomes and quality of life. For example, in April 2024, the Perth Blood Institute, an Australia-based nonprofit, reported that the number of people diagnosed with hemophilia, a genetic blood disorder that impairs blood clotting, increased to 257,146 in 2022 from 233,577 in 2021. As a result, the growing prevalence of rare blood disorders is fueling the expansion of the rare hematology market.

Companies in the rare hematology market are increasingly focusing on developing innovative therapies and establishing strategic initiatives, such as multi-stakeholder advocacy councils, to address unmet medical needs, enhance patient support, and drive solutions across various conditions. Multi-stakeholder advocacy councils bring together patients, caregivers, and experts to collaborate on improving care, awareness, and solutions for specific health conditions. For instance, in February 2023, Agios Pharmaceuticals Inc., a US-based biopharmaceutical company, launched the Red Cell Revolution advocacy advisory council. This initiative focuses on rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The council aims to strengthen community connections, generate published evidence, create practical solutions, and raise awareness of common challenges. It includes initiatives such as sponsored podcasts, video content, and partnerships with organizations such as the National Organization for Rare Disorders to promote health equity and education.

In October 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired Global Blood Therapeutics Inc. for an undisclosed amount. This acquisition allows Pfizer to expand its rare hematology portfolio, particularly in sickle cell disease, enhancing its pipeline of therapies for underserved patient populations. Global Blood Therapeutics Inc. is a US-based biopharmaceutical company focused on developing therapies for rare blood disorders, especially sickle cell disease.

Major players in the rare hematology market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Abbvie Inc., Bayer AG, Sanofi S.A., Novartis AG, Astrazeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring LLC, Biogen Inc., Jazz Pharmaceuticals Plc, Octapharma AG, PharmaEssentia Corporation, Disc Medicine Inc., BioInvent International AB, Mustang Bio Inc., BlueSphere Bio Inc., and Rallybio LLC.

North America was the largest region in the rare hematology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare hematology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare hematology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare hematology market includes revenues earned by entities through genetic testing, disease monitoring, blood transfusion support, patient care management, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Hematology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare hematology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for rare hematology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare hematology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Rare Hematology Market Characteristics

3. Rare Hematology Market Trends And Strategies

4. Rare Hematology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rare Hematology Growth Analysis And Strategic Analysis Framework

6. Rare Hematology Market Segmentation

7. Rare Hematology Market Regional And Country Analysis

8. Asia-Pacific Rare Hematology Market

9. China Rare Hematology Market

10. India Rare Hematology Market

11. Japan Rare Hematology Market

12. Australia Rare Hematology Market

13. Indonesia Rare Hematology Market

14. South Korea Rare Hematology Market

15. Western Europe Rare Hematology Market

16. UK Rare Hematology Market

17. Germany Rare Hematology Market

18. France Rare Hematology Market

19. Italy Rare Hematology Market

20. Spain Rare Hematology Market

21. Eastern Europe Rare Hematology Market

22. Russia Rare Hematology Market

23. North America Rare Hematology Market

24. USA Rare Hematology Market

25. Canada Rare Hematology Market

26. South America Rare Hematology Market

27. Brazil Rare Hematology Market

28. Middle East Rare Hematology Market

29. Africa Rare Hematology Market

30. Rare Hematology Market Competitive Landscape And Company Profiles

31. Rare Hematology Market Other Major And Innovative Companies

32. Global Rare Hematology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Hematology Market

34. Recent Developments In The Rare Hematology Market

35. Rare Hematology Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기